Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers

BACKGROUND: The anti-SLAMF7 monoclonal antibody, elotuzumab (elo), plus lenalidomide (len) and dexamethasone (dex) is approved for relapsed/refractory MM in the U.S. and Europe. Recently, a small phase 2 study demonstrated an advantage in progression-free survival (PFS) for elo plus pomalidomide (po...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer Res Clin Oncol
Main Authors: Hose, Dorothea, Schreder, Martin, Hefner, Jochen, Bittrich, Max, Danhof, Sophia, Strifler, Susanne, Krauth, Maria-Theresa, Schoder, Renate, Gisslinger, Bettina, Einsele, Hermann, Gisslinger, Heinz, Knop, Stefan
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2020
Assuntos:
Original Article – Clinical Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7810646/
https://ncbi.nlm.nih.gov/pubmed/32683487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03323-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados